Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.

FoxA1 (FOXA1) is a pioneering transcription factor of the androgen receptor (AR) that is indispensible for the lineage-specific gene expression of the prostate. To date, there have been conflicting reports on the role of FoxA1 in prostate cancer progression and prognosis. With recent discoveries of recurrent FoxA1 mutations in human prostate tumors, comprehensive understanding of FoxA1 function has become very important. Here, through genomic analysis, we reveal that FoxA1 regulates two distinct oncogenic processes via disparate mechanisms. FoxA1 induces cell growth requiring the AR pathway. On the other hand, FoxA1 inhibits cell motility and epithelial-to-mesenchymal transition (EMT) through AR-independent mechanism directly opposing the action of AR signaling. Using orthotopic mouse models, we further show that FoxA1 inhibits prostate tumor metastasis in vivo. Concordant with these contradictory effects on tumor progression, FoxA1 expression is slightly upregulated in localized prostate cancer wherein cell proliferation is the main feature, but is remarkably downregulated when the disease progresses to metastatic stage for which cell motility and EMT are essential. Importantly, recently identified FoxA1 mutants have drastically attenuated ability in suppressing cell motility. Taken together, our findings illustrate an AR-independent function of FoxA1 as a metastasis inhibitor and provide a mechanism by which recurrent FoxA1 mutations contribute to prostate cancer progression.

[1]  T. Kuzel,et al.  CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor , 2014, Oncogene.

[2]  今村 有佑.  FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway , 2013 .

[3]  M. Gleave,et al.  Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. , 2012, Molecular endocrinology.

[4]  Shahrokh F. Shariat,et al.  Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation , 2012, PloS one.

[5]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[6]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[7]  Gina M. Bernardo,et al.  FOXA1: a transcription factor with parallel functions in development and cancer. , 2012, Bioscience reports.

[8]  J. Carroll,et al.  FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate Cancer , 2012, Front. Endocrin..

[9]  Glen Kristiansen,et al.  Tumorigenesis and Neoplastic Progression FOXA 1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer , 2012 .

[10]  Jun Liu,et al.  Cooperation between Polycomb and androgen receptor during oncogenic transformation. , 2012, Genome research.

[11]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[12]  Dong Hu,et al.  Critical and Reciprocal Regulation of KLF4 and SLUG in Transforming Growth Factor β-Initiated Prostate Cancer Epithelial-Mesenchymal Transition , 2011, Molecular and Cellular Biology.

[13]  P. Nelson,et al.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. , 2011, Cancer cell.

[14]  O. Kallioniemi,et al.  Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer , 2011, The EMBO journal.

[15]  T. Hickey,et al.  FOXA1: master of steroid receptor function in cancer , 2011, The EMBO journal.

[16]  Sayaka Sekiya,et al.  Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors , 2011, Nature.

[17]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[18]  K. Kaestner,et al.  The FoxA factors in organogenesis and differentiation. , 2010, Current opinion in genetics & development.

[19]  Klaus H. Kaestner,et al.  FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis , 2010, Development.

[20]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[21]  Clifford A. Meyer,et al.  Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.

[22]  M. Washington,et al.  Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. , 2010, Cancer research.

[23]  Adrian V. Lee,et al.  Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM , 2009, Molecular and Cellular Biology.

[24]  Uma M. Muthurajan,et al.  Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. , 2009, Genes & development.

[25]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[26]  K. Kaestner,et al.  Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. , 2008, Genes & development.

[27]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[28]  C. Takimoto,et al.  Dietary genistein inhibits metastasis of human prostate cancer in mice. , 2008, Cancer research.

[29]  S. Dhanasekaran,et al.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. , 2007, Cancer cell.

[30]  M. Becich,et al.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process , 2007, BMC Cancer.

[31]  W. Catalona,et al.  Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification , 2006, Prostate Cancer and Prostatic Diseases.

[32]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[33]  Klaus H. Kaestner,et al.  The initiation of liver development is dependent on Foxa transcription factors , 2005, Nature.

[34]  L. Shaw.  Tumor cell invasion assays. , 2005, Methods in molecular biology.

[35]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[37]  Frank R. Lin,et al.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. , 2002, Molecular cell.

[38]  C. Woodcock,et al.  Nucleosome positioning by the winged helix transcription factor HNF3. , 1998, Genes & development.

[39]  C. Dinney,et al.  Metastatic model for human prostate cancer using orthotopic implantation in nude mice. , 1992, Journal of the National Cancer Institute.